Home > Publications Database > CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival. > print

001     282295
005     20251212103343.0
024 7 _ |a 10.1136/jnnp-2025-336208
|2 doi
024 7 _ |a pmid:40537251
|2 pmid
024 7 _ |a 0022-3050
|2 ISSN
024 7 _ |a 0266-8637
|2 ISSN
024 7 _ |a 0368-329X
|2 ISSN
024 7 _ |a 1468-330X
|2 ISSN
024 7 _ |a 2753-0477
|2 ISSN
024 7 _ |a 2753-0485
|2 ISSN
037 _ _ |a DZNE-2025-01265
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Verde, Federico
|0 0000-0002-3977-6995
|b 0
245 _ _ |a CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival.
260 _ _ |a London
|c 2025
|b BMJ Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765455387_17915
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Previous proteomic work has identified the somatodendritic protein MAP2 as a new candidate cerebrospinal fluid (CSF) biomarker for amyotrophic lateral sclerosis (ALS).We measured CSF levels of MAP2 and neurofilament light chain (NFL) in a retrospective cohort of 251 patients with ALS and 108 neurological controls (NCs).Patients with ALS had a higher median CSF MAP2 level compared with NCs, leading to an area under the curve (AUC) of 0.7080 (p<0.0001). They also had a higher median CSF NFL level (p<0.0001), resulting in an excellent diagnostic performance (AUC=0.9641; p<0.0001). Among patients with ALS, CSF MAP2 correlated with disease progression rate (DPR) (r=0.3099; p<0.0001) and was negatively associated with survival (HR=3.174). CSF NFL also correlated with DPR (r=0.4936; p<0.0001) and was negatively associated with survival (HR=2.759). The association of MAP2 with DPR was independent from NFL (p=0.0037). Stratifying patients based on median levels of both biomarkers resulted in significant differences in median survival times (low NFL/low MAP2, 66 months; high NFL/low MAP2 and vice versa, 35 months; high NFL/high MAP2, 26 months; p<0.0001). MAP2 was also associated with genetic status in patients with ALS, as patients with no mutations in C9ORF72 or in SOD1, as well as C9ORF72-positive ones, had higher median levels compared with NCs (p<0.0001), while patients with SOD1 mutations did not significantly differ from NCs (p>0.9999).Our study shows that the somatodendritic protein MAP2 is a promising candidate CSF biomarker for ALS.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ALS
|2 Other
650 _ 7 |a CSF
|2 Other
650 _ 7 |a MOTOR NEURON DISEASE
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 7 |a Microtubule-Associated Proteins
|2 NLM Chemicals
650 _ 7 |a MAP2 protein, human
|2 NLM Chemicals
650 _ 7 |a C9orf72 Protein
|2 NLM Chemicals
650 _ 7 |a Superoxide Dismutase-1
|0 EC 1.15.1.1
|2 NLM Chemicals
650 _ 7 |a C9orf72 protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: mortality
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Neurofilament Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Microtubule-Associated Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a C9orf72 Protein: genetics
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Superoxide Dismutase-1: genetics
|2 MeSH
700 1 _ |a Vávra, Jakub
|0 P:(DE-HGF)0
|b 1
|e First author
700 1 _ |a Dorst, J.
|0 P:(DE-2719)9001951
|b 2
|u dzne
700 1 _ |a Elmas, Zeynep
|b 3
700 1 _ |a Wiesenfarth, Maximilian
|b 4
700 1 _ |a De Gobbi, Anna
|b 5
700 1 _ |a Ratti, Antonia
|b 6
700 1 _ |a Poletti, Barbara
|0 0000-0003-4398-2051
|b 7
700 1 _ |a Tumani, Hayrettin
|0 P:(DE-2719)9002007
|b 8
700 1 _ |a Weishaupt, Jochen
|0 P:(DE-2719)9000455
|b 9
700 1 _ |a Silani, Vincenzo
|0 0000-0002-7698-3854
|b 10
700 1 _ |a Ticozzi, Nicola
|0 0000-0001-5963-7426
|b 11
700 1 _ |a Otto, Markus
|0 0000-0003-4273-4267
|b 12
700 1 _ |a Ludolph, Albert C
|0 P:(DE-2719)2812633
|b 13
|u dzne
700 1 _ |a Oeckl, Patrick
|0 P:(DE-2719)9001560
|b 14
|e Last author
773 _ _ |a 10.1136/jnnp-2025-336208
|g Vol. 96, no. 12, p. jnnp-2025-336208 -
|0 PERI:(DE-600)1480429-3
|n 12
|p 1132 - 1143
|t Journal of neurology, neurosurgery, and psychiatry
|v 96
|y 2025
|x 0022-3050
856 4 _ |u https://pub.dzne.de/record/282295/files/DZNE-2025-01265_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/282295/files/DZNE-2025-01265_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:282295
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9001951
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9002007
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812633
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9001560
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2024-12-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL NEUROSUR PS : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-28
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J NEUROL NEUROSUR PS : 2022
|d 2024-12-28
920 1 _ |0 I:(DE-2719)5000073
|k AG Öckl
|l Translational Mass Spectrometry and Biomarker Research
|x 0
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000073
980 _ _ |a I:(DE-2719)5000077
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21